Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310. 2 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева.
Список исп. литературыСкрыть список 1. Ахапкин Р. В. Анафранил СР — анафранил, улучшающий комплаенс (Обзор литературы). Психиатрия и психофармакотерапия. 2007; Т. 9 (3): 27–30. 2. Беккер Р. А., Быков Ю. В. Поль Кильхольц и его вклад в мировую психиатрию. Дневник психиатра. 2016; 03: 3–6. 3. Беккер Р. А., Быков Ю. В. Эффективность амисульприда в терапии депрессивных нарушений при шизофрении и других эндогенных психозах. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2016; 03: 19–26. 4. Бунькова К. М. Терапия непсихотической депрессии кломипрамином, пирлиндолом, эсциталопрамом: профили и частота побочных эффектов. Вестник неврологии, психиатрии и нейрохирургии. 2011; 11: 29–35. 5. Быков Ю. В., Беккер Р. А., Резников М. К. Депрессии и резистентность. Практическое руководство. М.: РИОР: ИНФРА-М., 2013. 374 с. 6. Быков Ю. В., Беккер Р. А., Сюняков Т. С. Зипрасидон: баланс между эффектами, эффективностью и переносимостью. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2016; 04: 52–62. 7. Быков Ю. В., Беккер Р. А. Арипризол — уникальный антипсихотик с широким спектром применения в психиатрии: факты и перспективы. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2017; 04: 30–47. 8. Костюкова Е. Г., Мосолов С. Н. Дифференцированный подход к применению антидепрессантов. Современная терапия психических расстройств. 2013; 3: 2–10. 9. Люст Е. Н. Разработка методики изолирования антидепрессанта кломипрамина из биологической жидкости (мочи). Современные проблемы науки и образования. 2015; 2 (2): 789. 10. Мазо Г. Э., Незнанов Н. Г. Терапевтически резистентные депрессии. — Санкт-Петербург, 2012. 448 с. 11. Мосолов С. Н., Костюкова Е. Г., Ладыженский М. Я. Алгоритм биологической терапии острого психоза рекуррентного депрессивного расстройства. Современная терапия психических расстройств. 2016; 3: 27–40. 12. Нуллер Ю. Л. Депрессия и деперсонализация Л.: Медицина, 1981: 207 с. 13. Симашкова Н. В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра. Эффективная фармакотерапия. 2011; 19: 44–50. 14. Albert A, Aguglia A, Bramante S, Bogetto F, Maina G. Treatment-resistant obsessive-compulsive disorder (OCD): current knowledge and open questions. Clin Neuropsychiatry. 2013;10(1):19–30. 15. Amsterdam JD, García-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84–90. 16. Ananth J. Clomipramine: an antiobsessive drug. Can J Psychiatry. 1986;31(3):253–8. 17. Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009;(25):3677–92. 18. Andrade C. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia. J Clin Psychiatry. 2012;73(11): e1362–4. 19. Bakker A, van Dyck R, Spinhoven P, van Balkom AJ. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999;60(12):831–8. 20. Barroso Cañizares A, Jiménez Cano JP, Granada Jiménez O. [Clomipramine in the treatment of catatonia]. [Article in Spanish]. Actas Esp Psiquiatr. 1999;27(4):273–6. 21. Brasic JR, Barnett JY, Kaplan D et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.Neurology. 1994;44(7):1309–12. 22. Brunton L, Chabner BA, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill Education. 12th Ed. 2011. 1808 p. ISBN 978-0071624428. 23. Buoli M, Caldiroli A, Altamura AC. Psychotic versus non-psychotic major depressive disorder: a comparative naturalistic study. Asian J Psychiatr. 2013;6(4):333–7. 24. Cavaljuga S, Licanin I, Kapić E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn J Basic Med Sci. 2003;3(3):27–31. 25. Conus P, Bondolfi G, Eap CB et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry. 1996;29(3):108–10. 26. DailyMed Reference on Anafranil. Веб-сайт dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4074b555-7635-41a9-809d-fae3b3610059. Доступ проверен 23.01.2018. 27. De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol Psychiatry. 1992;32(4):369–74. 28. Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder.Neuropsychiatr Dis Treat. 2010;6:233–42. 29. Di Michele V, Bolino F. A novel treatment option of bipolar depression with psychotic and catatonic features. Gen Hosp Psychiatry. 2006;28(4):364–5. 30. Fekkes D, Timmerman L, Pepplinkhuizen L. Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression.Eur Neuropsychopharmacol. 1997;7(3):235–9. 31. Fernandez CE, Lopez-Ibor JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso-Españolas de Neurologia Psiquiatria y Ciencias Afines. 1967;26:119–47. 32. Frazer A, Winokur A. Biological Foundations of Mental Disorders. Pañstwowy Zaklad Wydawnictw Lekarskich, Warszawa, 1982. 33. Geller DA, Biederman J, Stewart SE et al. Which SSRI? a meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160(11):1919–28. 34. Gervasoni N, Aubry JM, Gex-Fabry M et al. Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? Pharmacol Res. 2009;59(3):202–6. 35. Gloger S, Grunhaus L, Gladic D et al. Panic attacks and agoraphobia: low dose clomipramine treatment. J Clin Psychopharmacol. 1989;9(1):28–32. 36. Gordon CT, State RC, Nelson JE et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50(6):441–7. 37. Hale AS, Procter AW, Bridges PK. Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. Br J Psychiatry. 1987;151:213–7. 38. Hermesh H, Hoffnung RA, Aizenberg D et al. Catatonic signs in severe obsessive compulsive disorder. J Clin Psychiatry. 1989;50(8):303–5. 39. Hoffart A, Due-Madsen J, Lande B et al. Clomipramine in the treatment of agoraphobic in patients resistant to behavioral therapy. J Clin Psychiatry. 1993;54(12):481–7. 40. Inoue T, Kitaichi T, Ogawa T. [Therapeutic strategy for drug resistant depression]. [Article in Japanese]. Seishin Shinkeigaku Zasshi. 2004;106(8):1016–23. 41. Kalinin VV, Maksimova MA. [The clinico-psychopathological characteristics of patients with panic disorders and the efficacy of clomipramine therapy]. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 1993;93(6):46–50. 42. Karameh WK, Khani M. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder. Int J Neuropsychopharmacol. 2015;19(2). 43. Kielholz P, Terzani S, Gastpar M, Adams C. [Treatment of therapy-resistant depressions. Results of combined infusion treatment]. [Article in German]. Schweiz Med Wochenschr. 1982;112(31-32):1090–5. 44. Koran LM, McElroy SL, Davidson JR et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. J Clin Psychopharmacol. 1996;16(2):121–129. 45. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997;154(3):396–401. 46. Kragh-Sorensen P, Muller B, Andersen JV. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Journal of Clinical Psychopharmacology 1995;15(Suppl.2):248–303. 47. Laux G, Reimer F. [Treatment of therapy resistant depressions with high dose clomipramine]. [Article in German]. Int Pharmacopsychiatry. 1979;14(5):294–9. 48. Lopez-Ibor JJ, Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996;6(2):111–118. 49. Marcourakis T, Gorenstein C, Gentil V. Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects. J Psychopharmacol. 1993;7(4):325–30. 50. McDougle CJ, Price LH, Volkmar FR et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31(4):746–50. 51. McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.Drugs. 1990;39(1):136–53. 52. Medscape Reference on Anafranil. Веб-сайт reference.medscape.com/drug/ anafranil-clomipramine-342938. Доступ проверен 23.01.2018. 53. Millan MJ, Gobert A, Lejeune F et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther. 2001;298(2):565–80. 54. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992;12(4):251–61. 55. Monsma FJ Jr, Shen Y, Ward RP et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43(3):320–7. 56. Mukai Y, Two A, Jean-Baptiste M. Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. BMJ Case Rep. 2011; pii: bcr0220113858. 57. Papp LA, Schneier FR, Fyer AJ et al. Clomipramine treatment of panic disorder: pros and cons.J Clin Psychiatry. 1997;58(10):423–5. 58. Peters MD, Davis SK, Austin LS. Clomipramine: an antiobsessional tricyclic antidepressant. Clin Pharm. 1990;9(3):165–78. 59. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder.Psychiatr Clin North Am. 2014;37(3):375–91. 60. Piwowarska J, Wrzosek M, Radziwoń-Zaleska M et al. Serum cortisol concentration in patients with major depression after treatment with clomipramine.Pharmacol Rep. 2009;61(4):604–11. 61. Reynghe de Voxrie GV. Anafranil (G34586) in obsessive neurosis. Acta Neurolgia Belgica. 1968;68:787–92. 62. Ruat M, Traiffort E, Leurs R et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A. 1993;90(18):8547–51. 63. Sasson Y, Iancu I, Fux M et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol. 1999;9(3):191–6. 64. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. Cambridge University Press. 1st Ed. 2009. 186 p. ISBN 978-0521874984. 65. Stahl SM. Stahl’s essential psychopharmacology: Case studies. Cambridge university press, 2015. 66. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013. 67. Suhara T, Takano A, Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60(4):386–91. 68. Vogel B, Hagler M, Hennessey A. Dose dependent decrements in adult male rat sexual behavior after neonatal clomipramine treatment. Pharmacol, Biochemi and Behavi 1996;54(3):605–9. 69. Wada K, Suzuki H, Taira T et al. Successful use of intravenous clomipramine in depressive-catatonic state associated with corticosteroid treatment. Int J Psychiatry Clin Pract. 2004;8(2):131–3. 70. Warneke L. Intravenous chlorimipramine therapy in obsessive-compulsive disorder. Can J Psychiatry. 1989;34(9):853–9. 71. Warneke LB. The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder.Can J Psychiatry. 1984;29(2):135–41. 72. Williams DA. Foye’s Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 7th Ed. 2012. 1520 p. ISBN 978-1609133450. 73. Yaryura-Tobias JA, Neziroglu FA. Obsessive-Compulsive Disorder Spectrum: Pathogenisis, Diagnosis, and Treatment. Amer Psychiatric Pub Inc. 1st Ed. 1997. 321 p. ISBN 978-0880487078. 74. Zohar J. Obsessive Compulsive Disorder: Current Science and Clinical Practice (World Psychiatric Association). Wiley-Blackwell. 1st Ed.2012. 358 p. ISBN 978-0470711255.